Focusing on five specific drugs not officially approved for use on the NHS, we asked how many applications they had received from patients in the last financial year - and how many had been granted.
The drugs in question were, Avastin, for colon and breast cancer, Erbitux, for colon and lung cancer, Nexavar, for renal and liver cancer, Sutent, for renal cancer, and Tarceva, for lung and pancreatic cancer.
Access to the drugs was tightest in London, and easiest in the North West of England.
However, there were wide variations, even between neighbouring authorities and in some areas no requests for the drugs had been made.
EAST ANGLIA - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
Primary Care Trust
|
Avastin (Becacizumab) colon and breast cancer
|
Erbitux (Cetuximab) colon and lung cancer
|
Tarceva (Erlotinib) lung and pancreas cancer
|
Sutent (Sunitinib) renal cancer
|
Nexavar (Sorafenib) renal and liver cancer
|
Total - requests granted/total applications (%)
|
| Cambridgeshire
|
0/0
|
0/0
|
2/6
|
5/6
|
1/2
|
8/14 (57.1%)
|
| East and North Hertfordshire /West Hertfordshire
|
0/less than 5
|
0/greater than 10
|
less than 5/more than 5
|
less than 5/ more than 10
|
less than 5/more than 5
|
Will not give exact figures due to patient confidentiality
|
| Great Yarmouth and Waveney
|
0/0
|
0/2
|
1/1
|
0/1
|
No data
|
1/4 (25%)
|
| Mid Essex
|
1/1
|
0/1
|
0/2
|
4/4
|
0/0
|
5/8 (62.5%)
|
| Norfolk
|
0/2
|
1/2
|
1/1
|
1/6
|
3/5
|
6/16 (37.5%)
|
| North East Essex
|
0/0
|
0/0
|
1/2
|
0/0
|
3/3
|
4/5 (80%)
|
| Peterborough
|
0/0
|
0/0
|
2/2
|
0/0
|
0/0
|
2/2 (100%)
|
| South East Essex
|
Had no applications for any of the drugs
|
|
|
|
|
N/A
|
| South West Essex
|
No data
|
|
|
|
|
N/A
|
| Suffolk
|
N/A
|
0/1
|
0/0
|
0/1
|
5/5
|
5/7 (71.4%)
|
| West Essex PCT
|
3/3
|
1/1
|
2/3
|
1/1
|
1/1
|
8/9 (88.9%)
|
Return
EAST MIDLANDS - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Bassetlaw
|
0/1
|
0/0
|
0/1
|
3/3
|
0/0
|
3/5 (60%)
|
| Derby City
|
0/0
|
0/0
|
0/0
|
1/3
|
0/0
|
1/3 (33.3%)
|
| Derbyshire County
|
1/1
|
0/0
|
0/1
|
1/4
|
0/0
|
2/6 (33.3%)
|
| Leicester City/ Leicestershire
|
0/0
|
1/4
|
6/6
|
14/16
|
0/1
|
21/27 (77.8%)
|
| Lincolnshire Teaching
|
0/1
|
1/2
|
2/2
|
1/2
|
0/6
|
4/13 (36.7%)
|
| North Lincolnshire
|
1/1
|
0/0
|
0/0
|
1/4
|
n/a
|
2/8 (25%)
|
| Northamptonshire Teaching
|
0/1
|
0/0
|
8/12
|
7/12
|
0/2
|
14/27 (51.8%)
|
| Nottingham City
|
0/0
|
0/0
|
0/0
|
0/3
|
0/3
|
0/6 (0%)
|
| Nottinghamshire County Teaching
|
1/3
|
1/1
|
1/1
|
3/ 6
|
0/0
|
6/11 (54.5%)
|
| Tameside and Glossop
|
2/2
|
1/1
|
0/0
|
1/1
|
0/0
|
4/4 (100%)
|
Return
LONDON - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Barking and Dagenham
|
1/1
|
1/2
|
1/1
|
0/0
|
0/0
|
3/4 (75%)
|
| Barnet
|
0/4
|
0/1
|
1/2
|
0/7
|
0/2
|
1/16 (6.3%)
|
| Bexley
|
1/2
|
1/2
|
0/2
|
0/5
|
0/1
|
2/12 (16.7%)
|
| Brent Teaching
|
0/0
|
1(1)*/2
|
1/3
|
2/4
|
0/0
|
4/8 (50%)
|
| Bromley
|
0/2
|
0/1
|
4/7
|
4/9
|
0/0
|
8/19 (42.1%)
|
| Camden
|
No data
|
|
|
|
|
|
| City and Hackney Teaching
|
0/0
|
1/3
|
5/9
|
1/1
|
0/0
|
7/13 (53.8%)
|
| Croydon
|
5 or less/5 or less
|
0/0
|
5 or less all refused
|
5 or less/5 or less
|
5 or less all refused
|
N/A
|
| Ealing
|
0/1
|
1 (for 3 months)/1
|
0/0
|
1/1
|
0/0
|
2/3 (66.7%)
|
| Enfield
|
0 of 0
|
0 of 2
|
5 of 9
|
4 of 4
|
0 of 1
|
9/16 (56.2%)
|
| Greenwich Teaching
|
2/2
|
0/1
|
2/3
|
1/2
|
0/2
|
5/10 (50%)
|
| Hammersmith and Fulham
|
No data
|
|
|
|
|
|
| Haringey Teaching
|
0/0
|
0/0
|
1/4
|
3/3
|
0/0
|
4/7 (57%)
|
| Harrow
|
0/0
|
0/0
|
1/1
|
1/2
|
0/0
|
2/3 (66.7%)
|
| Havering
|
10/10
|
1/1
|
3/3
|
1/1
|
0/0
|
15/15 (100%)
|
| Hillingdon
|
0/2
|
0/5
|
0/0
|
1/2
|
0/1
|
1/10 (10%)
|
| Hounslow
|
0/1
|
0/2
|
0/0
|
0(1)*/4
|
0/1
|
0/7 (0%)
|
| Islington
|
1(1)*/2
|
0/0
|
5(1)*/8
|
0/0
|
0/3
|
6/11 (54.5%)
|
| Kensington and Chelsea
|
0/0
|
0/2
|
1/1
|
0/0
|
0/2
|
1/5 (20%)
|
| Kingston
|
0/0
|
0/0
|
0/0
|
0/2
|
0/0
|
0/2 (0%)
|
| Lambeth
|
0/0
|
0/0
|
5/6
|
5/6
|
0/3
|
10/15 (66.7%)
|
| Lewisham
|
0/0
|
0/3
|
1/1
|
6/6
|
1/1
|
8/11 (72.7%)
|
| Newham
|
0/0
|
0/0
|
2/3
|
0/0
|
0/0
|
2/3 (66.7%)
|
| Richmond and Twickenham
|
0/1
|
0/1
|
0/0
|
0/1
|
(1)*/1
|
0/3 (0%)
|
| Southwark
|
0 of 0
|
1 of 2
|
4 of 8
|
7 of 9
|
0 of 0
|
12/19 63.2%
|
| Sutton and Merton
|
0/0
|
0/0
|
0/3
|
3/11
|
1/1
|
4/15 (%)
|
| Tower Hamlets
|
No data
|
|
|
|
|
|
| Waltham Forest
|
1/1
|
0/0
|
2/2
|
0/0
|
1/1
|
4/4 (100%)
|
| Wandsworth
|
0/0
|
0/0
|
0/1
|
0/1
|
0/0
|
0/2 (0%)
|
| Westminster
|
0/0
|
0/2
|
1/4
|
1/3
|
0/0
|
2/9 (22.2%)
|
*
application withdrawn
Return
NORTHERN IRELAND - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
Combined results on behalf of all four health and social services boards
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Combined results are on behalf of all four health and social services boards
|
0/ less than 5 requests
|
0/ less than 5 requests
|
Unknown /less than 5
|
16/16
|
0/0
|
N/A
|
Return
NORTH EAST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| County Durham/ Darlington
|
0/0
|
1/1
|
1(2)*/4
|
0/1
|
0/1
|
2/7 (32.6%)
|
| Gateshead/ South of Tyne and Wear/ Sunderland
|
Information not held
|
|
|
|
|
|
| Hartlepool/ Middlesbrough/ North Tees/ Redcar and Cleveland
|
No applications
|
Not routinely funded
|
Routinely funded
|
Routinely funded
|
Not routinely funded
|
N/A
|
| Newcastle/ North Tyneside/ Northumberland
|
0/3
|
0/1
|
5/7
|
1/2
|
0/1
|
6/14 (42.9%)
|
* application withdrawn
Return
NORTH WEST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Ashton, Leigh and Wigan
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
N/A
|
| Blackburn With Darwen
|
0/0
|
0/1
|
0/0
|
2(1)*/3
|
1/1
|
3/5 (60%)
|
| Blackpool
|
0/0
|
0/0
|
0/0
|
1/1
|
0/1
|
1/2 (50%)
|
| Bolton
|
0/0
|
0/0
|
0/0
|
4/4
|
0/0
|
4/4 (100%)
|
| Bury
|
0/0
|
0/0
|
0/0
|
2/2
|
0/1
|
2/3 (66.7%)
|
| Central & Eastern Cheshire
|
0/0
|
0/0
|
0/0
|
8/8
|
0/0
|
8/8 (100%)
|
| Central Lancashire
|
0/0
|
0/0
|
1/1
|
4/5
|
1/2
|
6/8 (75%)
|
| Cumbria Teaching
|
1/3
|
0/1
|
2/2
|
4/4
|
0/1
|
7/11 (63.6%)
|
| East Lancashire Teaching
|
0/0
|
1/1
|
0/0
|
13/13
|
1/1
|
15/15 (100%)
|
| Halton and St Helens
|
No applications
|
Automatically funded
|
Automatically funded
|
Automatically funded
|
Automatically funded
|
N/A
|
| Heywood, Middleton and Rochdale
|
0/0
|
2/2
|
0/0
|
1/1
|
0/0
|
3/3 (100%)
|
| Knowsley
|
0/0
|
0/0
|
0/0
|
1/1
|
0/0
|
1/1 (100%)
|
| Liverpool
|
Low requests
|
0/0
|
Low requests
|
Low requests
|
0/0
|
N/A
|
| Manchester
|
0/0
|
0/0
|
0/0
|
0/3
|
0/0
|
0/3 (0%)
|
| North Lancashire Teaching
|
No data
|
|
|
|
|
|
| Oldham
|
0/0
|
0/1
|
0/0
|
3/3
|
0/0
|
3/4 (75%)
|
| Salford
|
1/1
|
1/1
|
0/0
|
1/3
|
0/0
|
3/5 (60%)
|
| Sefton
|
0/2
|
0/0
|
0/0
|
0/0
|
0/0
|
0/2 (0%)
|
| Stockport
|
0/0
|
0/0
|
0/0
|
3/5
|
0/0
|
3/5 (60%)
|
| Tameside and Glossop
|
2/2
|
1/1
|
0/0
|
1/1
|
0/0
|
4/4 (100%)
|
| Trafford
|
7/7
|
3/3
|
0/0
|
3/4
|
0/0
|
13/14 (92.9%)
|
| Warrington
|
No data
|
|
|
|
|
|
| Western Cheshire
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
N/A
|
| Wirral
|
0/0
|
0/0
|
1/1
|
2/2
|
0/0
|
3/3 (100%)
|
* application withdrawn
Return
SCOTLAND - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Ayrshire and Arran
|
0/0
|
0/0
|
N/A
|
0/0
|
0/1
|
0/1(0%)
|
| Borders
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0 (0%)
|
| Dumfries and Galloway
|
0/0
|
0/0
|
0/0
|
0/2
|
0/0
|
0/2 (0%)
|
| Fife
|
0/0
|
0/0
|
N/A
|
1/1
|
|
1/1 (100%)
|
| Forth Valley
|
0/0
|
0/1
|
N/A
|
1/1
|
0/0
|
1/2 (50%)
|
| Grampian
|
0/0
|
2/2
|
|
1/3 ( 2 under discussion)
|
0/0
|
3/5
|
| Greater Glasgow and Clyde
|
0/0
|
0/2
|
|
0/0
|
0/7
|
0/9 (0%)
|
| Highland
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
N/A
|
| Lanarkshire
|
0/0
|
0/1
|
|
0/0
|
0/0
|
0/0 (0%)
|
| Lothian
|
0/1
|
0/0
|
n/a
|
0/5
|
0/2
|
0/8 (0%)
|
| Orkney
|
|
|
|
|
|
|
| Shetland
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
N/A
|
| Tayside
|
0/0
|
1/1
|
|
0/3
|
0/3
|
1/7 (14.3%)
|
| Western Isles
|
No data
|
|
|
|
|
|
Return
THE SOUTH EAST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
Primary Care Trust
|
Avastin (Becacizumab) colon and breast cancer
|
Erbitux (Cetuximab) colon and lung cancer
|
Tarceva (Erlotinib) lung and pancreas cancer
|
Sutent (Sunitinib) renal cancer
|
Nexavar (Sorafenib) renal and liver cancer
|
Total - requests granted/total applications (%)
|
| Bedfordshire
|
0/1
|
1/1
|
3(1)*/4
|
2(1)*/4
|
1(2)*/4
|
7/14 (50%)
|
| Berkshire East
|
0/0
|
0/11
|
0/3
|
3/9
|
0/0
|
3/23 (13.0%)
|
| Berkshire West
|
1/1
|
1/1
|
1/2
|
7/8
|
2/2
|
12/14 (85.7%)
|
| Buckinghamshire
|
1/2
|
0/1
|
4/6
|
13/15
|
0/0
|
18/24 (75%)
|
| East Sussex Downs and Weald / Hastings and Rother
|
Do not provide Avastin
|
Do not provide Erbitux
|
Will provide if patient meets their criteria
|
Will provide if patient meets their criteria
|
Will provide if patient meets their criteria
|
Will not state number of applications
|
| Eastern and Coastal Kent
|
0/0
|
2/4
|
0/3
|
4/10
|
6/6
|
12/23 (52.2%)
|
| Hampshire
|
0/3
|
1/2
|
2/8
|
0/7
|
0/2
|
3/22 (13.6%)
|
| Isle Of Wight
|
1/2
|
0/3
|
0/0
|
0/2
|
0/0
|
1/7 (14.3%)
|
| Luton
|
1/2 (1 awaiting decision)
|
1/1
|
0/0
|
1 awaiting decision
|
1 awaiting decision
|
2/5 (40%)
|
| Medway
|
0/0
|
1/1
|
0/0
|
0/0
|
0/0
|
1/1 (100%)
|
| Milton Keynes
|
0/0
|
0/0
|
1/3
|
1/1
|
0/0
|
2/4 (50%)
|
| Oxfordshire
|
0/0
|
0/0
|
2/2
|
1/13
|
0/1
|
3/17 (17.6%)
|
| Portsmouth City Teaching
|
0/0
|
0/0
|
0/0
|
1/1
|
0/1
|
1/2 (50%)
|
| Southampton City
|
0/0
|
0/0
|
0/0
|
1/1
|
0/0
|
1/1 (100%)
|
| Surrey
|
0/1
|
0/5
|
3/17
|
19/29
|
0/4
|
22/56 (39%)
|
| Sutton and Merton
|
0/0
|
0/0
|
0/3
|
3/11
|
1/1
|
4/15 (26.7%)
|
| West Kent
|
0/0
|
0/2
|
3/10
|
4/11
|
2/7
|
9/30 (30%)
|
| West Sussex
|
0/4
|
0/0
|
0(1)*/5
|
11/11
|
0/3
|
11/23 (47.8%)
|
* application withdrawn
Return
THE SOUTH WEST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
Primary Care Trust
|
Avastin (Becacizumab) colon and breast cancer
|
Erbitux (Cetuximab) colon and lung cancer
|
Tarceva (Erlotinib) lung and pancreas cancer
|
Sutent (Sunitinib) renal cancer
|
Nexavar (Sorafenib) renal and liver cancer
|
Total - requests granted/total applications (%)
|
| Bath and North East Somerset
|
1/1
|
0/0
|
0/0
|
2/4
|
0/1
|
3/6 (50%)
|
| Bournemouth and Poole Teaching PCT
|
No information held
|
|
|
|
|
|
| Bristol
|
0/0
|
0/0
|
Since Oct 2006, low number for Tarceva
|
Since Oct 2006, 9 requests for Sutent and Sorafenib
|
Since Oct 2006, 9 requests for Sutent and Sorafenib
|
N/A
|
| Cornwall and Isles Of Scilly PCT
|
1/1
|
1/2
|
5/6
|
6/6
|
0/1
|
13/16 (81.3%)
|
| Devon PCT
|
0/3
|
1/4
|
18/19
|
12/15
|
0/2
|
31/43 (72.1%)
|
| Dorset PCT
|
0/0
|
0/0
|
1/3
|
5/8
|
1/1
|
7/12 (58.3%)
|
| Gloucestershire
|
0/3
|
0/0
|
1/3
|
2/4
|
0/0
|
3/10 (30%)
|
| North Somerset
|
0/0
|
0/0
|
2/4
|
0/1
|
0/0
|
2/5 (40%)
|
| Plymouth Teaching
|
0/0
|
0/0
|
2/3
|
0/1
|
4/4
|
6/8 (75%)
|
| Somerset
|
No data
|
No data
|
No data
|
8/10*
|
No data
|
N/A
|
| South Gloucestershire
|
0/0
|
0/0
|
0/1
|
0/1
|
1/3
|
1/5 (20%)
|
| Swindon
|
0/0
|
0/0
|
1/1
|
0/1
|
1/1
|
2/3 (66.6%)
|
| Wiltshire
|
2/3
|
0/0
|
5/5
|
0/4
|
0/0
|
7/12 (58.3%)
|
* Funded 8/10 requests for Sutent, and less than 5/6 , in 2006-08. Did not provide data for each year. For the other drugs there may have been less than five applications made or funded
Return
WALES - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Anglesey
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
N/A
|
| Blaenau Gwent
|
1/1
|
*
|
*
|
0/0
|
0/0
|
1/1(100%)
|
| Bridgend
|
0/0
|
0/0
|
4/4
|
1/1
|
0/0
|
5/5 (100%)
|
| Caerphilly
|
No data
|
No data
|
0/less than 5
|
0/less than 5
|
0/0
|
N/A
|
| Cardiff
|
0/2
|
0/0
|
0/1
|
2/4
|
0/0
|
2/7(28.5%)
|
| Carmarthenshire
|
No data
|
|
|
|
|
|
| Ceredigion
|
0/0
|
1/2
|
0/0
|
0/3
|
0/0
|
1/5(20%)
|
| Conwy
|
0/0
|
0/0
|
0/0
|
0/0
|
0/0
|
N/A
|
| Denbighshire
|
0/0
|
0/0
|
0/0
|
less than5/ less than 5
|
0/0
|
|
| Flintshire
|
No data
|
|
|
|
|
N/A
|
| Gwynedd
|
0/less than 5
|
0/0
|
less than 5/less than 5
|
0/0
|
0/less than five
|
N/A
|
| Merthyr Tydfil
|
0/0
|
0/0
|
less than 5/ less than 5
|
0/0
|
0/0
|
N/A
|
| Monmouthshire
|
0/0
|
0/0
|
1/1
|
0/0
|
0/0
|
1/1 (100%)
|
| Neath Port Talbot
|
No data
|
|
|
|
|
|
| Newport
|
0/0
|
0/0
|
0/less than 5
|
0/0
|
less than 5/less than 5
|
N/A
|
| Pembrokeshire
|
1/1
|
2/4
|
2/2
|
3/4
|
0/0
|
8/11(72.7%)
|
| Powys
|
No data
|
Since 2006, 30% of all requests approved
|
Since 2006, 30% of all requests approved
|
No data
|
Since 2006, 30% of all requests approved
|
N/A
|
| Rhondda Cynon Taff
|
0/0
|
Less than 5/ less than 5
|
Less than 5/less than 5
|
less than 5/less than 5
|
0/less than 5
|
N/A
|
| Swansea
|
0/1
|
1/5
|
0/2
|
0/1
|
0/4
|
1/13(7.6%)
|
| Torfaen
|
No data
|
No data
|
No data
|
All approved/less than 5
|
0/0
|
N/A
|
| Vale of Glamorgan
|
No data
|
|
|
|
|
|
| Wrexham
|
0/0
|
0/0
|
Less than 5/less than 5
|
0/0
|
0/0
|
N/A
|
*For Erbitus and Tarceva allocation made available to support agreement in 16 LBH's in south east and mid and west Wales
Return
THE WEST MIDLANDS- NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
Primary Care Trust
|
Avastin (Becacizumab) colon and breast cancer
|
Erbitux (Cetuximab) colon and lung cancer
|
Tarceva (Erlotinib) lung and pancreas cancer
|
Sutent (Sunitinib) renal cancer
|
Nexavar (Sorafenib) renal and liver cancer
|
Total - requests granted/total applications (%)
|
| Birmingham East and North
|
0/2
|
1/2
|
0/6
|
5/6
|
0/2
|
6/18 (33.3%)
|
| Coventry Teaching
|
0/0
|
0/0
|
0/0
|
0/1
|
0/1
|
0/2 (0%)
|
| Dudley
|
0/4
|
1/3
|
1/4
|
1/4
|
0/0
|
3/15 (20%)
|
| Heart Of Birmingham Teaching
|
1/2
|
0/0
|
0/0
|
3/6
|
0/0
|
4/8 (50%)
|
| Herefordshire
|
No information available
|
|
|
|
|
|
| North Staffordshire
|
1/1
|
0/1
|
1/4
|
0/0
|
1/3
|
3/9 (33.3%)
|
| Sandwell*
|
1/2
|
1/1
|
1/1
|
6/6
|
1/2
|
N/A
|
| Shropshire County
|
0/0
|
4/5
|
pending/1
|
0/0
|
0/0
|
4/6 (66.7%)
|
| South Birmingham
|
0/1
|
0/0
|
3/4
|
6/9
|
2/6
|
11/20 (55%)
|
| South Staffordshire
|
0/2
|
1/4
|
2/5
|
3/4
|
0/5
|
6/20 (30%)
|
| Stoke On Trent
|
1/2
|
0/0
|
0/1
|
0/0
|
0/0
|
1/3 (33.3%)
|
| Telford and Wrekin
|
0/0
|
0/0
|
0/0
|
1/1
|
0/1
|
1/2 (50%)
|
| Walsall Teaching
|
0/0
|
7/7
|
1/1
|
5/8
|
1/1
|
14/17 (82.4%)
|
| Warwickshire
|
0/0
|
0/0
|
0/1
|
3/7
|
0/0
|
3/8 (37.5%)
|
| Wolverhampton City
|
Will not break figures down for fear of undermining patient confidentiality
|
|
|
|
|
|
| Worcestershire
|
2/5
|
0/0
|
3/3
|
4/14
|
1/1
|
10/23 (43.5%)
|
*PCT will only provide combined figures for 2006-2008 for fear of undermining patient confidentiality
Return
YORKSHIRE AND HUMBERSIDE - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
|
PCT
|
Avastin (Becacizumab) for Colon and Breast Cancer
|
Erbitux (Cetuximab) for Colon and lung Cancer
|
Tarceva (Erlotinib) for Lung and Pancreas Cancer
|
Sutent (Sunitinib) for Renal Cancer
|
Nexavar(Sorafenib) for Renal and Liver Cancer
|
Total - requests granted/total applications (%)
|
| Barnsley
|
0/0
|
0/2
|
0/0
|
4/4
|
0/0
|
4/6 (66.7%)
|
| Bradford and Airedale Teaching
|
No info given
|
|
|
|
|
|
| Calderdale
|
No breakdown given - have funded
|
No breakdown given - have funded
|
No breakdown given - have funded
|
|
|
N/A
|
| Doncaster
|
1/1
|
0/1
|
12/12
|
7/7
|
0/0
|
20/21 (90.7%)
|
| East Riding Of Yorkshire
|
1/2
|
1/2
|
6/7
|
10/12
|
1/1
|
19/24 (79.2%)
|
| Hull Teaching
|
0/2
|
0/0
|
3/3
|
4/4
|
0/1
|
7/10 (70%)
|
| Kirklees
|
0/0
|
0/0
|
1/1
|
2/2
|
0/0
|
3/3 (100%)
|
| Leeds
|
1/1
|
0/0
|
30/30
|
12/23
|
0/0
|
43/54 (79.6%)
|
| North Yorkshire and York
|
0/1
|
1/2
|
0/6
|
1/10
|
0/1
|
2/20 (10%)
|
| Rotherham
|
0/0
|
1/2
|
1/1
|
2/2
|
|
4/5 (80%)
|
| Sheffield
|
0/0
|
1/5
|
1/3
|
11/13
|
0/0
|
13/21 (61.9%)
|
| Wakefield District
|
0/0
|
0/0
|
3/3
|
1/1
|
0/0
|
4/4 (100%)
|
Return
One-Minute World News
~RS~a~RS~International~RS~q~RS~~RS~z~RS~08~RS~){kind=small}
~RS~q~RS~~RS~z~RS~08~RS~)
© MMIX
Bookmark with:
What are these?